Ahmed M. Bayoumi




Dr. Ahmed Bayoumi is a Scientist at MAP Centre for Urban Health Solutions at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, where he is also a general internist and Human Immunodeficiency Virus (HIV) physician. He holds the Fondation Baxter and Alma Ricard Chair in Inner City Health at St. Michael’s Hospital and the University of Toronto and is a Professor in the Department of Medicine and in the Institute of Health Policy, Management and Evaluation at the University of Toronto. He is a Senior Adjunct Scientist at ICES. He has extensive experience in translating research to policy (member of the Canadian Drug Expert Committee, past Scientific Director of Converge3, past president of the international Society for Medical Decision Making, and past Director of Clinical Epidemiology and Health Care Research at the University of Toronto). He has co-led large multi-method studies, including the highly impactful Toronto and Ottawa Supervised Consumption Assessment (TOSCA) and the Marginalization and COVID-19 (MARCO) studies. His research interests include the delivery of health services, particularly to people who use drugs, people living with HIV, and other marginalized populations. He is a member of HMRAC (the Homelessness, Mortality, Research and Advocacy Coalition), an academic – community collaboration that meets regularly to discuss how research can address issues related to homelessness.

Recent Publications

  1. Harris, MTH, Young, S, Barocas, J, Bayoumi, AM, Caudarella, A, Laurence, G et al.. A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto. Public Health Rep. 2021; :333549211032974. doi: 10.1177/00333549211032974. PubMed PMID:34269625 .
  2. Perri, M, Guta, A, Gagnon, M, Bonn, M, Leece, P, Bayoumi, AM et al.. Developing a digital health strategy for people who use drugs: Lessons from COVID-19. Digit Health. ;7 :20552076211028404. doi: 10.1177/20552076211028404. PubMed PMID:34262782 PubMed Central PMC8243112.
  3. Rowlands Snyder, EC, Boucher, LM, Bayoumi, AM, Martin, A, Marshall, Z, Boyd, R et al.. A cross-sectional study of factors associated with unstable housing among marginalized people who use drugs in Ottawa, Canada. PLoS One. 2021;16 (7):e0253923. doi: 10.1371/journal.pone.0253923. PubMed PMID:34197552 PubMed Central PMC8248707.
  4. Ewees, MGE, Abdel-Bakky, MS, Bayoumi, AMA, Abo-Saif, AA, Altowayan, WM, Alharbi, KS et al.. Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway. J Adv Res. 2021;31 :127-136. doi: 10.1016/j.jare.2020.12.014. PubMed PMID:34194837 PubMed Central PMC8240102.
  5. Refaie, MMM, Shehata, S, Bayoumi, AMA, El-Tahawy, NFG, Abdelzaher, WY. The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity. Cardiovasc Drugs Ther. 2021; :. doi: 10.1007/s10557-021-07214-x. PubMed PMID:34185243 .
  6. Tan, DHS, Tavangar, F, Fusca, L, Ross, P, Hull, MW, Grennan, T et al.. Interest in Hypothetical Preexposure Prophylaxis Against Herpes Simplex Virus: A Cross-Sectional Survey. Sex Transm Dis. 2021;48 (8):e105-e108. doi: 10.1097/OLQ.0000000000001342. PubMed PMID:34110756 .
  7. Charest, M, Sharma, M, Chris, A, Schnubb, A, Knox, DC, Wilton, J et al.. Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada. PLoS One. 2021;16 (3):e0248626. doi: 10.1371/journal.pone.0248626. PubMed PMID:33735209 PubMed Central PMC7971529.
  8. Kendall, CE, Boucher, LM, Donelle, J, Martin, A, Marshall, Z, Boyd, R et al.. Engagement in primary health care among marginalized people who use drugs in Ottawa, Canada. BMC Health Serv Res. 2020;20 (1):837. doi: 10.1186/s12913-020-05670-z. PubMed PMID:32894114 PubMed Central PMC7487534.
  9. Latimer, EA, Rabouin, D, Cao, Z, Ly, A, Powell, G, Aubry, T et al.. Cost-Effectiveness of Housing First With Assertive Community Treatment: Results From the Canadian At Home/Chez Soi Trial. Psychiatr Serv. 2020;71 (10):1020-1030. doi: 10.1176/appi.ps.202000029. PubMed PMID:32838679 .
  10. Beshay, ON, Ewees, MG, Abdel-Bakky, MS, Hafez, SMNA, Abdelrehim, AB, Bayoumi, AMA et al.. Resveratrol reduces gentamicin-induced EMT in the kidney via inhibition of reactive oxygen species and involving TGF-β/Smad pathway. Life Sci. 2020;258 :118178. doi: 10.1016/j.lfs.2020.118178. PubMed PMID:32739468 .
Search PubMed

Affiliations & Other Activities

  • Scientist, MAP Centre for Urban Health Solutions, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Professor, Institute of Health Policy, Management and Evaluation, University of Toronto